Ten intriguing novel agents in early development to watch out for
Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.
Do we need to target the adenosine fog as well as TIGIT in NSCLC?
A look at some hidden gems in the ASCO program and what it all means in terms of the science.
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
Every now and again something intriguing comes along, which generates a flurry of interest from our…
Science drives oncology new product development and the AACR special conferences are always a good place…
Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20
A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview
Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider
New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...
Through the keyhole with a look at AZN and MedImmune's IO portfolio
A look a the updated adenosine pathway landscape and how it is progressing
Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.
Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.
Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company